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Abstract
Background: Peroxisome proliferator activated receptor alpha (PPARa) regulates lipids metabolism and inhibits
inflammatory response. However, the role of PPARa in alcoholic liver disease is largely unknown. We aim to
elucidate the effect and the molecular basis of PPARa in ethanol induced hepatic injury in mice.
Results: C57BL/6J mice fed with 4% ethanol-containing Lieber-DeCarli liquid diet for 12 weeks exhibited hepatocyte
steatosis, necrosis and inflammatory infiltration, accompanied with elevated serum alanine aminotransferase (ALT) and
aspartic transaminase (AST) levels, decreased hepatic expression of PPARa, lipids oxidation promoting genes and anti-
inflammatory factors, as well as enhanced hepatic expression of fatty acids synthesis promoting genes and pro-
inflammatory cytokines. Induction of PPARa by PPARa agonist WY14643 treatment for 2 weeks ameliorated the severity
of liver injury and restored expression of genes altered by ethanol treatment. However, administration of PPARa
antagonist GW6471 for 2 weeks promoted the inflammatory response.
Conclusions: The present study provided the evidence for the protective role of PPARa in ameliorating ethanol
induced liver injury through modulation of the genes related to lipid metabolism and inflammatory response.
Keywords: Peroxisome proliferator activated receptor alpha, ethanol, steatohepatitis, animal experiment
Background
Alcoholic liver injury is a progressive process encompass-
ing hepatic steatosis and steatohepatitis. The latter may
progress to liver fibrosis, cirrhosis and even hepatocellular
carcinoma [1]. Chronic ethanol exposure impairs fatty
acid oxidation and enhances lipogenesis by targeting key
transcriptional regulators of genes controlling these meta-
bolic processes, including peroxisome proliferators acti-
vated receptor gamma coactivator 1 alpha (PGC-1a) [2],
sterol regulatory element binding protein 1 (SREBP-1) and
its downstream genes, such as fatty acid synthase (FAS)
[2], resulting in the accumulation of triglyceride in the
liver (steatosis). Fat accumulation renders the liver more
susceptible to other injuries. Ethanol also contributes to
the up-regulation of pro-inflammatory factors, osteopontin
(OPN) [3-5] and cyclooxygenase-2 (COX-2) [6] in the
liver, which promotes inflammatory injury and causes
alcoholic steatohepatitis. Pharmacological treatment for
patient with alcoholic steatohepatitis is still not available.
There is compelling need to identify agent to protect liver
against ethanol-related inflammatory injury.
Peroxisome proliferator activated receptor alpha
(PPARa), interacts with the retinoid X receptor to func-
tion as a transcription factor to induce the expression of
a series of genes involved in fatty acid transport, mito-
chondrial fatty acid oxidation, catabolism, and inflam-
matory responses [7-11]. Down-regulation and/or
dysfunction of PPARa are involved in the development
of ethanol induced liver injury [11]. However, the role
of PPARa in pathogenesis of alcoholic liver disease
(ALD) remains largely unknown. In this study, we inves-
tigated the effects of PPARa activation in evolution of
alcoholic steatohepatitis and the molecular basis of its
action in animal experiments.
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Activation of PPARa by WY14643 lowered the serum
levels of alanine aminotransferase (ALT) and aspartic
transaminase (AST) in mice fed with ethanol liquid diet
A ss h o w ni nF i g u r e1 ,m i c ef e dw i t h4 %e t h a n o l -
containing Lieber-DeCarli liquid diet for 12 weeks
showed significantly higher serum ALT and AST levels
(P < 0.001) compared with Control group, indicating
hepatic injury. A significant reduction of serum ALT
and AST levels (P < 0.001) was noticed after WY14643
treatment. However, GW6471 treatment further elevated
the ALT level (P < 0.01) than those fed ethanol liquid
diet only (Figure 1).
Activation of PPARa ameliorated liver injury in mice fed
with ethanol liquid diet
The liver sections from mice fed with ethanol-containing
liquid diet exhibited disordered lobule structure, hepato-
cyte ballooning, moderate steatosis, inflammatory infiltra-
tion and mild hepatocyte necrosis. WY14643 significantly
ameliorated hepatic steatosis and inflammation (P < 0.001)
(Figure 2).
Activation of PPARa improved ultrastructural damage of
hepatocytes in mice fed with ethanol liquid diet
Rich organelles including mitochondria, endoplasmic reti-
culum and ribosomes are observed in hepatocytes of nor-
mal control livers under electron microscopy. Whilst, in
the liver sections of ethanol feeding mice, mitochondrial
damage in hepatocytes with broken cristae, ruptured
membranes and merged cristae/membranes are observed.
Granule fusion and degranulation phenomenons are also
found in rough endoplasmic reticulum. These ultrastruc-
tural changes in hepatocytes are clearly improved by
WY14643 administration (Figure 2C).
Hepatic expression of PPARa and PPARa-responsive
genes in mice fed with ethanol liquid diet and treated
with WY14643 or GW6471
A ss h o w ni nF i g u r e3 ,h e p atic expression of PPARa
mRNA (P < 0.05) and protein (P < 0.05), as well as
PPARa-responsive genes cytochrome P450 4A10
(CYP4A10) (P <0 . 0 0 1 )a n dC Y P 4 A 1 4( P <0 . 0 1 )m R N A
was down-regulated by ethanol. WY14643 administration
increased the expression levels of PPARa (P < 0.05),
CYP4A10 (P < 0.001) and CYP4A14 (P < 0.001). However,
GW6471 reduced PPARa (P < 0.05) and CYP4A14 (P <
0.001) mRNA expression.
Induction of PPARa regulates hepatic expression of lipid
metabolism related genes
To seek an explanation for the ameliorated hepatic steato-
sis under WY14643 administration, we assessed the hepa-
tic expression levels of genes involved in lipid metabolism.
Relative to control mice, hepatic FAS mRNA (P <0 . 0 0 1 )
and protein (P < 0.001) were enhanced, while sirtuin 1
(SIRT1) mRNA (P < 0.001) and protein (P < 0.001) as well
as PGC-1a protein (P < 0.01) were reduced in mice fed
with ethanol liquid diet. Administration of WY14643
increased mRNA and protein expressions of fibroblast
growth factor 21 (FGF21) (P < 0.001 and P < 0.01, respec-
tively), SIRT1 (P < 0.05 and P < 0.01), PGC-1a (P < 0.001
and P < 0.001), down-regulated FAS expression (P < 0.001
and P < 0.05) as compared with mice fed ethanol liquid
diet only (Figure 4). GW6471 decreased the FGF21
mRNA (P < 0.001) and protein (P < 0.05) expression,
while increased FAS mRNA (P < 0.01) expression in mice
fed with ethanol.
Activation of PPARa suppressed hepatic expression of
pro-inflammatory factors
We further evaluated the role of PPARa in the develop-
ment of ethanol induced liver injury by assessing the hepa-
tic expression levels of pro-inflammatory factors
phosphatidylinositol 3-kinase (PI3K), OPN and COX-2.
We found that ethanol increased the expression of PI3K,
OPN and COX-2. Mice treated with WY14643 showed
significantly reduced hepatic mRNA and protein expres-
sion for PI3K (P < 0.001 and P < 0.01, respectively), OPN
(P <0 . 0 0 1a n dP <0 . 0 0 1 )a n dC O X - 2( P <0 . 0 1a n dP <
0.05) as compared with mice fed with ethanol liquid diet
only (Figure 5). On the other hand, GW6471 further
Figure 1 Effects of ethanol with treatment of WY14643 or GW6471 on serum (A) ALT level and (B) AST level. Data are expressed as the
mean ± SD (n = 6 per group). ***P < 0.001 compared with Control group;
##P < 0.01,
###P < 0.001 compared with Ethanol group.
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0.05) expression, but didn’t affect OPN expression.
Activation of PPARa enhanced hepatic expression of
adiponectin and heme oxygenase-1 (HO-1)
Hepatic mRNA and protein expression of adiponectin, a
major anti-inflammatory adipokine, and HO-1, a key anti-
oxidative stress factor, were evaluated by RT-PCR and
Western blot. WY14643 up-regulated mRNA and protein
expression for adiponectin (P < 0.001 and P < 0.01, respec-
tively) and for HO-1 (P < 0.001 and P < 0.001) in mice fed
with ethanol liquid diet (Figure 6). GW6471 didn’ta l t e r
expression of these two genes (Figure 6).
Discussion
C57BL/6J mice fed with 4% ethanol-containing Lieber-
DeCarli liquid diet for 12 weeks showed hepatic steato-
sis, hepatocyte ballooning, inflammatory cell infiltration
and hepatocyte necrosis, accompanied with elevated
serum ALT and AST levels. Under transmission elec-
tron microscopy, we found that mitochondrial cristae
were broken, the membranes were ruptured, and most
of the cristae were merged with parts of the membranes.
These results indicated that this ALD mouse model
mimicked the human alcoholic liver injury.
PPARa, a member of the nuclear hormone receptor
superfamily and a receptor for free fatty acid (FFA) [12-14],
represses hepatic lipid accumulation by regulating the
expression of genes involved in fatty acid synthesis, oxida-
tion and storage. It is also inhibited inflammatory response
via inhibiting transcription of nuclear factor-B and pro-
duction of inflammatory cytokines [11]. In this study, we
found PPARa expression was down-regulated accompa-
nied by the development of ethanol induced hepatic injury.
Induction of PPARa by WY14643 treatment for 2 weeks
attenuated ethanol induced liver injury, as evidenced by
diminished histological steatosis and inflammatory
response, improved hepatocyte ultrastructure, as well as
Figure 2 Changes of liver histopathology and hepatocyte ultrastructure in mice under various treatment conditions. (A) Hematoxylin
and eosin stained liver sections from mice liver (Original magnification, ×200), (B) Effect of PPARa on scores for hepatic steatosis, hepatocyte
ballooning, necroinflammation in ethanol induced liver injury, and (C) Electron microscopy for hepatocyte ultrastructure (×20 000). N, nucleus;
LD, lipid droplets; M, mitochondria; R, rough endoplasmic reticulum. ***P < 0.001 compared with Control group;
###P < 0.001 compared with
Ethanol group.
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PPARa antagonist GW6471 for 2 weeks increased hepatic
inflammation. These results indicated that PPARa might
play an important protective role in the pathogenesis of
ALD.
We further explored the potential mechanisms of the
protective effect of PPARa by the use of selective agonist
WY14643. Ethanol and its metabolic products impair tri-
carboxylic acid cycle activity and fatty acid b-oxidation in
the mitochondria, resulting in FFA overload and triglycer-
ide accumulation in the liver, ultimately leading to hepatic
steatosis. Characteristic PPARa target genes CYP4A10
and CYP4A14 are involved in fatty acid oxidation in a
PPARa-dependent manner [15]. Hepatic CYP4A10 and
CYP4A14 mRNA expression could be reduced by ethanol
and restored by WY14643. FGF21, a hormone primarily
produced by liver and fat tissue, was reported to improve
lipid metabolism [16-18]. In this study, hepatic FGF21
expression was enhanced by WY14643. In addition, the
metabolic effect of FGF21 depends on the activation of its
downstream signaling cascade involving the SIRT1 axis
[16-18]. The latter had been reported to be responsible for
PGC-1a activation and SREBP-1 reduction in the liver
[19,20]. We found that WY14643 restored the hepatic
expression of SIRT1 which was reduced by alcohol admin-
istration in mice. Induction of SIRT1 enhanced mitochon-
drial oxidative capacity as demonstrated by increases in
oxygen consumption and citrate synthase activity, as well
Figure 3 Effect of WY14643 on hepatic PPARa and PPARa-responsive genes expression in ethanol induced liver injury. (A1) Expression
level of PPARa mRNA and (A2) protein; (B) Expression level of CYP4A10 mRNA; (C) Expression level of CYP4A14 mRNA in various treatment
groups. Data are expressed as the mean ± SD (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Control group;
#P < 0.05,
##P
< 0.01,
###P < 0.001 compared with Ethanol group.
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1a [21], a crucial metabolic mediator for coordinating glu-
coneogenesis and fatty acid oxidation in the liver [22-24].
In keeping with this observation, induction of PPARa by
WY14643 in this study induced the hepatic expression of
PGC-1a. Besides, SIRT1 repressed lipogenesis largely by
attenuating the activity of SREBP-1 and its downstream
gene FAS [20,25-28]. In this connection, downregulation
Figure 4 Effect of PPARa induction by WY14643 on hepatic lipid metabolism related genes expression in ethanol induced liver injury. (A1)
Expression level of FGF21 mRNA and (A2) protein; (B1) Expression level of SIRT1 mRNA and (B2) protein; (C1) Expression level of PGC-1a mRNA and
(C2) protein; (D1) Expression level of FAS mRNA and (D2) protein in various treatment groups. Data are expressed as the mean ± SD (n = 6 per
group). *P <0 . 0 5 ,* * P < 0.01, ***P < 0.001 compared with Control group;
#P <0 . 0 5 ,
##P <0 . 0 1 ,
###P < 0.001 compared with Ethanol group.
Figure 5 Effect of PPARa induction by WY14643 on hepatic expression of pro-inflammatory factors. (A1) Expression level of PI3K mRNA
and (A2) protein; (B1) Expression level of OPN mRNA and (B2) protein; (C1) Expression level of COX-2 mRNA and (C2) protein in various
treatment groups. Data are expressed as the mean ± SD (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Control group;
#P < 0.05,
##P < 0.01,
###P < 0.001 compared with Ethanol group.
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SIRT1 axis has also emerged as a major signaling system
in regulating adiponectin signaling in the lipid lowering
action [29,30]. We also found that WY14643 increased
adiponectin expression and down-regulated hepatic
expression of PI3K in ethanol feeding mice, the latter has
been reported to participate in the adipogenesis of human
mesenchymal stem cells [31] and promote steatosis in cul-
tured hepatocytes exposed to methionine-choline deficient
(MCD) medium [32]. Collectively, the anti-steatosis effect
of PPARa may be partly related to up-regulation of its tar-
get genes CYP4A10 and CYP4A14, induction of SIRT1
axis by up-regulation of FGF21 and adiponectin expres-
sion, as well as down-regulation of FAS and PI3K
expression, which ameliorated hepatic steatosis induced by
ethanol consumption.
Ethanol treatment results in fatty acids accumulation in
the liver. Fatty acids are substrate of cytochrome P450
2 E 1( C Y P2 E 1 ) .I n d u c t i o no fC Y P2 E 1b yf a t t ya c i d si sa
major source of reactive oxygen species (ROS), which
evokes oxidative stress and mitochondrial damage in the
hepatocytes, in turn worsens fatty acid b-oxidation disor-
der and hepatic steatosis. Furthermore, ROS activates
and sensitizes Kupffer cells, which produce and release
pro-inflammatory cytokines, triggering hepatic inflamma-
tory response [11]. PI3K could induce expression of
OPN, which increased ALT release by hepatocytes trea-
ted with MCD medium [32], indicating that PI3K and
Figure 6 Effect of PPARa induction by WY14643 on expression of hepatic adiponectin and HO-1. (A1) Expression level of adiponectin
mRNA and (A2) protein; (B1) Expression level of HO-1 mRNA and (B2) protein in various treatment groups. Data are expressed as the mean ±
SD (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Control group;
##P < 0.01,
###P < 0.001 compared with Ethanol group.
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hepatocyte damage. Elevated level of OPN, a chemoat-
tractant molecule, correlated with neutrophil infiltration
[4], and neutralizing antibody against OPN prevented
neutrophil infiltration and ethanol induced liver injury
[5]. Pro-inflammatory factor COX-2 was induced by
ethanol as well. In our study, activation of PPARa
resulted in the inhibition of these key hepatic inflamma-
tory regulators including PI3K, OPN and COX-2 expres-
sion. In this regard, the anti-inflammatory effects of
PPARa in ethanol induced steatohepatitis may be related
to inhibition of these pro-inflammatory factors.
Besides regulating lipid metabolism in the liver, adipo-
nectin serves as an anti-inflammatory factor. Adiponectin
prevents hepatic injury by inhibiting the synthesis and/or
release of tumor necrosis factor-a (TNF-a)[ 3 3 ] .H O - 1
plays essential role in mediating the anti-inflammatory
function of adiponectin. Importantly, after chronic ethanol
exposure, induction of HO-1 protects mice from the sensi-
tizing effect of ethanol on LPS-stimulated TNF-a expres-
sion [34]. In addition, HO-1 and its down-stream
mediator carbon monoxide could increase expression of
anti-inflammatory cytokine interleukin-10 in macrophages
[35]. In this study, HO-1 expression was up-regulated by
PPARa agonist. In keeping with our findings, Otterbein et
al. reported that PPARa could regulate HO-1 transcrip-
tion directly by binding to a PPAR-responsive element in
the promoter regions of HO-1 [36]. Thus, PPARa induced
HO-1 expression by itself and/or via increasing adiponec-
tin expression may contribute to the amelioration of etha-
nol induced hepatic inflammatory response.
Conclusions
The present study showed a protective role of PPARa in
ethanol induced liver injury. Activation of PPARa by
WY14643 ameliorated hepatic steatosis through increasing
lipids oxidation promoting genes CYP4A10, CYP4A14,
FGF21, adiponectin, SIRT1 and PGC-1a expression, and
suppressing fatty acid synthesis promoting genes FAS and
PI3K expression. Induction of PPARa attenuated liver
inflammatory response by repressing expression of pro-
inflammatory cytokines PI3K, OPN and COX-2, as well as
enhancing expression of anti-inflammatory factors adipo-
nectin and HO-1. PPARa agonist administration might
serve as an effective therapeutic strategy for ALD.
Materials and methods
Animals and treatments
Eight-week-old male C57BL/6J mice with body weight
between 20-25 g were obtained from the Experimental
Animal Center of Chinese Academy of Medical Sciences,
and were bred in a temperature-controlled animal facility
with a 12 h light-dark cycle. They had free access to water
and were allowed to adapt to their food and environment
for 1 week before the start of the experiment. The mice
were randomly divided into 4 groups (6 mice per group):
1) Control group: fed with non-alcohol control liquid diet;
2) Ethanol group: fed with 4% ethanol-containing Lieber-
DeCarli liquid diet; 3) Ethanol plus WY14643 (Ethanol
+WY) group: fed with ethanol liquid diet supplemented
with WY14643 (50 mg/kg/d, Cayman Chemical, Ann
Arbor, MI, CA); 4) Ethanol plus GW6471 (Ethanol+GW)
group: fed with ethanol liquid diet plus GW6471 (10 mg/
kg, Tocris bioscience, Bristol, UK), three times/week,
intraperitoneal injection. The ethanol concentration was
raised gradually from 2% to 4% within 2 weeks, and then
the mice were fed a 4% ethanol-containing Lieber-DeCarli
liquid diet for 12 weeks. PPARa agonist WY14643 and
antagonist GW6471 were administrated in the last 2
weeks. Control mice were fed with the same volume of a
control liquid diet prepared by replacing ethanol in the
Lieber-DeCarli liquid diet with isocaloric maltose. Animals
were sacrificed after overnight fasting at the end of experi-
ment. Blood samples were collected from femoral artery
for biochemical analysis. Livers were weighed, frozen or
fixed in 10% formalin for histological analysis, fixed in 4%
glutaraldehyde for electron microscopy, or snap-frozen in
lipid nitrogen followed by storage at -80°C in a freezer
until required. All the protocols and procedures were per-
formed following the guidelines of the Hebei Committee
for Care and Use of Laboratory Animals and were
approved by the Animal Experimentation Ethics Commit-
tee of the Hebei Medical University.
Biochemical analysis
Serum ALT and AST levels were measured by enzy-
matic method using an automatic biochemical analyzer
(Olympus UA2700, Japan) according to the manufac-
turer’s instructions.
Histological analysis
Haematoxylin and eosin stained paraffin-embedded liver
sections (5 μmt h i c k )w e r es c o r e da sf o l l o w s :( a )d e g r e e
of steatosis (0 ≤ 10%, 1 = 10-33%, 2 = 33-66%, 3 ≥ 66%);
(b) degree of hepatocyte ballooning (0 = none, 1 = mild
and moderate, 2 = severe); (c) degree of necroinflamma-
tion (0 = none, 1 = mild, 2 = moderate, 3 = severe) in
accordance with a scoring system for ALD designed by
Dominguez et al. [37].
Transmission electron microscopy (TEM) examination
The tissue fixed in 4% glutaraldehyde solution was post-
fixed in 1.5% osmium tetroxide solution, dehydrated,
and fixed firmly into polybed resin. Micro-thin sections
were performed and stained with lead citrate and uranyl
acetate for a Hitachi model 7500 TEM examination.
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chain reaction (qRT-PCR) analysis of hepatic mRNA
expression
Total RNA was isolated from liver tissues using Trizol
Reagent (Tiangen Biotech, Beijing, China) according to the
manufacturer’s instructions. The hepatic mRNA levels of
PPARa, CYP4A10, CYP4A14, FGF21, SIRT1, PGC-1a,
F A S ,P I 3 K ,O P N ,C O X - 2 ,a d i p o n e c t i na n dH O - 1w e r e
determined by qRT-PCR using the ABI PRISM 7500
sequence detection system (Applied Biosystems, Foster,
CA) with SYBR Green Reagent (Tiangen Biotech). Expres-
sion levels of the target genes were normalized against an
endogenous reference gene glyceraldehydes 3-phosphate
dehydrogenase (GAPDH). The specific primer sequences
were listed in Table 1. All data were obtained using
Sequence Detector Software (Applied Biosystems).
Western blot analysis of hepatic protein expression
Total protein was extracted and concentration was mea-
sured by the Bradford method (DC protein assay; Bio-Rad,
H e r c u l e s ,C A ) .E q u a la m o u n t so fp r o t e i n( 1 0 0μg/well)
were loaded onto 12% SDS-PAGE for each sample and pro-
teins were transferred onto equilibrated polyvinylidene
difluoride membranes (Millipore Corporation, Billerica,
MA) by electroblotting. The membranes were incubated
with primary antibodies of PPARa, FGF21, SIRT1, PGC-
1a, FAS, PI3K, OPN, COX-2, adiponectin, HO-1, and
b-actin (Santa Cruz Biotechnology, Santa Cruz, CA),
respectively, overnight at 4°C. Membranes were further
incubated with secondary antibody for 1 h at room tem-
perature. Proteins were detected by enhanced chemilumi-
nescence (Santa Cruz Biotechnology). The amount of
protein expression was corrected by that of b-actin in the
same sample and the bands were quantified by scanning
densitometry using the digital Kodak Gel Logic 200 (Care-
stream Molecular Imaging, Woodbridge, CT).
Statistical analysis
All data are expressed as mean ± standard deviation (SD).
Statistical analysis on the data was performed by one-way
analysis of variance (ANOVA) or Kruskal-Wallis H test,
with the least significant difference-t (LSD-t)t e s to r
mann-whitney u test for post-hoc comparison using SPSS
13.0 (v. 13.0; SPSS Inc., Chicago, IL), and P-value below
0.05 was considered significant.
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Table 1 Primer sequences used for real-time RT-PCR
analysis
Gene Product length Primer sequences
PPARa 149 bp F 5’-GATGTCACACAATGCAATTCG-3’
R5 ’-GGTAGGCTTCGTGGATTCTCT-3’
CYP4A10 64 bp F 5’-ACACTGCTCCGCTTCGAACT-3’
F5 ’-CAAGTCGGGCTAAGGGCA-3’
CYP4A14 81 bp F 5’-AAGGCAGTGTTCAGTTGGATG-3’
F5 ’-GGCGAAAGAAAGTCAGGTTGT-3’
FGF21 199 bp F 5’-CAGATGACGACCAAGACACTG-3’
R5 ’-TCAAAGTGAGGCGATCCATAG-3’
SIRT1 197 bp F 5’-ACGCTGTGGCAGATTGTTATTA-3’
R5 ’-GCAAGGCGAGGCATAGATACC-3’
PGC-1a 109 bp F 5’-AGGAACAGCAGCAGAGACAAAT-3’
R5 ’-CTGGGGTCAGAGGAAGAGATAA-3’
FAS 193 bp F 5’-GGGTTCTAGCCAGCAGAGTCTA-3’
R5 ’- TGAGGTTGCTGTCGTCTGTAGT-3’
PI3K 198 bp F 5’- GCACGGCGATTACACTCTTAC-3’
R5 ’-TTGGACACTGGGTAGAGCAAC-3’
OPN 121 bp F 5’-GGTGATAGCTTGGCTTATGGAC-3’
R5 ’-CCTTAGACTCACCGCTCTTCAT-3’
COX-2 122 bp F 5’-GCCTTCTCCAACCTCTCCTACT-3’
R5 ’-ACCTTTTCCAGCACTTCTTTTG-3’
adiponectin 202 bp F 5’-CCAGTATCAGGAAAAGAATGTGG-3’
R5 ’-TGGTGTATGGGCTATGGGTAGT-3’
HO-1 427 bp F 5’-AACAAGCAGAACCCAGTCTATG-3’
R5 ’-TGAGCAGGAAGGCGTCTTA-3’
GAPDH 233 bp F 5’-GGTGAAGGTCGGTGTGAACG-3’
R5 ’-CTCGCTCCTGGAAGATGGTG-3’
Abbreviations: PPARa, peroxisome proliferator activated receptor alpha;
CYP4A10, cytochrome P450 4A10; CYP4A14, cytochrome P450 4A14; FGF21,
fibroblast growth factor 21; SIRT1, Sirtuin 1; PGC-1a, PPAR gamma coactivator
1a; FAS, fatty acid synthase; PI3K, phosphatidylinositol 3-kinase; OPN,
osteopontin; COX-2, cyclooxygenase 2; HO-1, heme oxygenase-1; GAPDH,
glyceraldehyde-3- phosphate dehydrogenase.
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